Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...

Novo Nordisk's stock fell after semaglutide's Alzheimer's news. Click here for how strong fundamentals and growth catalysts ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 6, 2025 /PRNewswire/ -- At ObesityWeek® (November 4-7 in Atlanta, GA), Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial ...

Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish drugmaker seeks to demonstrate health benefits beyond ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Danish pharma major Novo Nordisk (NOV: N) has presented new post-hoc analyses from the Phase III REDEFINE 1 trial evaluating CagriSema (cagrilintide/semaglutide), an investigational injectable ...

Novo Nordisk said on Monday that two late-stage trials testing an older oral version of its semaglutide drug failed to meet ...

Please provide your email address to receive an email when new articles are posted on . Adults receiving CagriSema in REDEFINE 1 had significant reductions in blood pressure at 20 weeks that were ...

With CagriSema treatment, systolic blood pressure was reduced by -10.9 mmHg over 68 weeks (versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo). * This reduction was seen regardless of ...

A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications to ...